Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 3/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468038 | 1.00 | CA12 (0.49) | CA12CA1CA7CA14AKT1 | |
| SCHEMBL19790268 | 1.00 | CA12 (0.49) | CA12CA1CA7CA14AKT1 | |
| SCHEMBL13614219 | 0.87 | CA12 (0.51) | CA12CA1CA7CA14AKT1 | |
| SCHEMBL14199162 | 0.87 | CA12 (0.48) | CA12CA1CA7CA14AKT1 | |
| SCHEMBL8292151 | 0.85 | CA12 (0.49) | CA12CA1CA7CA14AKT1 | |
| SCHEMBL28298458 | 0.84 | PPARG (0.44) | CTSLALDH1A1CTSKPPARAPPARG | |
| SCHEMBL28199962 | 0.84 | MEN1 (0.52) | CA12CA1CTSSALDH1A1SYK | |
| SCHEMBL28199963 | 0.84 | MEN1 (0.52) | CA12CA1CTSSALDH1A1SYK | |
| SCHEMBL14266632 | 0.83 | ALDH1A1 (0.58) | CA12CA1CA7CA14AKT1 | |
| SCHEMBL1486201 | 0.82 | CA12 (0.47) | CA12CA1CA7CA14AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120965-B1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS INC (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8415497-B2 | N-halogenated amino compounds and derivatives | NOVABAY PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415497-B2 | N-halogenated amino compounds and derivatives | NOVABAY PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-1689713-B1 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE | MERCK SHARP & DOHME (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2008083347-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-7354942-B2 | Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354942-B2 | Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354942-B2 | Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2008-04-08 | — | — | US | disclosed |
| CN-101061113-A | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK & CO INC (US) | 2007-10-24 | — | — | CN | disclosed |
| US-20070088165-A1 | preventing the formation of insoluble A beta and arresting the production of A beta; beta-site amyloid precursor protein-cleaving enzyme; 3-[(2-amino-2-methyl-3-phenylpropoxy)methyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]-[methyl(methylsulfonyl)amino]benzamide | MERCK SHARP & DOHME LLC | 2007-04-19 | — | — | US | disclosed |
| US-20070088165-A1 | preventing the formation of insoluble A beta and arresting the production of A beta; beta-site amyloid precursor protein-cleaving enzyme; 3-[(2-amino-2-methyl-3-phenylpropoxy)methyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]-[methyl(methylsulfonyl)amino]benzamide | MERCK SHARP & DOHME LLC | 2007-04-19 | — | — | US | disclosed |
| CN-1942467-A | 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO INC (US) | 2007-04-04 | — | — | CN | disclosed |
| WO-2005051914-A1 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088165-A1 | preventing the formation of insoluble A beta and arresting the production of A beta; beta-site amyloid precursor protein-cleaving enzyme; 3-[(2-amino-2-methyl-3-phenylpropoxy)methyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]-[methyl(methylsulfonyl)amino]benzamide | BACE1, BACE2, APP | CA12 3765/4885CA1 979/4885CA7 3420/4885 |
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | DCTD, DDC, DAO | CA12 4784/4885CA1 4664/4885CA7 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.